Business Context and Reporting Period
Company: Castle Biosciences, Inc. (CSTL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: A commercial-stage diagnostics company providing personalized, clinically actionable information for dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. The company operates a single reportable segment focused on the U.S. market.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Revenues | $83,043 | $85,782 | $257,219 | $245,758 |
| Net (Loss) Income | $(501) | $2,269 | $(21,826) | $8,655 |
| Operating (Loss) Income | $(6,804) | $5,079 | $(38,983) | $4,620 |
| Gross Margin % | 74.7% | 79.2% | 66.8% | 79.3% |
| Cash & Cash Equivalents | $85,556 | $94,959 (End Q3 2024) | Balance Sheet: $85,556 (Sep 30, 2025) | |
| Marketable Securities | $201,986 | $173,421 (Dec 31, 2024) | Balance Sheet: $201,986 (Sep 30, 2025) | |
| Long-Term Debt | $10,049 | $9,745 (Dec 31, 2024) | Balance Sheet: $10,049 (Sep 30, 2025) | |
| Operating Cash Flow (9M) | N/A | $37,416 | $40,501 |
Material Changes vs. Prior Period
- Revenue Mix Shift: Q3 2025 revenues decreased 3.2% year-over-year. This was driven by a $16.5 million decline in dermatologic revenue (primarily DecisionDx-SCC due to loss of Medicare coverage) offset by a $13.8 million increase in non-dermatologic revenue (driven by TissueCypher volume growth).
- Profitability Decline: The company reported a net loss of $0.5 million for Q3 2025 compared to net income of $2.3 million in Q3 2024. For the nine months ended September 30, 2025, the net loss was $21.8 million compared to net income of $8.7 million in the prior year period.
- Amortization Spike: Amortization of acquired intangible assets increased significantly to $32.6 million for the nine months ended September 30, 2025 (vs. $6.8 million in 2024). This was primarily due to the accelerated amortization of the IDgenetix test asset following its discontinuation in May 2025 and the acquisition of Capsulomics.
- Test Volume Growth: Despite revenue headwinds, total test report volume increased 8.1% for the nine months ended September 30, 2025. TissueCypher volume grew 90.5%, while DecisionDx-Melanoma grew 6.3%.
- Equity Investment Gains: The company recognized $3.6 million in unrealized gains on equity securities in Q3 2025, a new line item not present in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Discontinued Operations: The IDgenetix mental health test was discontinued in May 2025. The related intangible asset was fully amortized by March 31, 2025, resulting in a $20.1 million acceleration of expense.
- Reimbursement Risks: Medicare coverage for the DecisionDx-SCC test was lost effective April 24, 2025. The company has submitted reconsideration requests, but the outcome remains uncertain. This has materially impacted the average selling price (ASP) and revenue for this product line.
- Acquisitions: In May 2025, the company acquired Capsulomics (Previse) for $18.7 million in cash plus up to $2.5 million in contingent consideration. This acquisition adds the AdvanceAD-Tx test, planned for a limited launch in November 2025.
- Liquidity: The company holds $287.5 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months. A $25 million credit line under the 2024 Loan and Security Agreement expired on September 30, 2025, with no draws made.
- Capital Expenditures: Significant capital spending is ongoing for the construction of a new corporate headquarters in Friendswood, Texas, with a total expected cost of approximately $44.2 million.
- Regulatory Environment: The FDA rescinded its final rule on Laboratory Developed Tests (LDTs) in September 2025 following a court ruling. The company continues to operate under current state and federal oversight.
Investor Verification Checklist
- Medicare Reimbursement Status: Verify the status of the reconsideration requests for DecisionDx-SCC coverage with Novitas and MolDX, as this directly impacts future revenue stability.
- AdvanceAD-Tx Launch: Monitor the November 2025 launch of the AdvanceAD-Tx test and initial adoption rates to assess the return on the Capsulomics acquisition.
- Capital Burn Rate: Track cash flow against the $44.2 million headquarters construction project and ongoing operational expenses to ensure liquidity remains sufficient beyond the 12-month horizon.
- Test Volume vs. Revenue: Analyze the divergence between growing test volumes (especially TissueCypher) and declining dermatologic revenue to understand the impact of reimbursement constraints on unit economics.
- Equity Securities Valuation: Review the composition and volatility of the $8.9 million equity securities portfolio, as unrealized gains/losses are impacting net income.